Limits...
The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis.

Shen H, Min R, Tan Q, Xie W, Wang H, Pan H, Zhang L, Xu H, Zhang X, Dai J - Arch Med Sci (2015)

Bottom Line: In the present study, the efficacy and safety of recombinant human interleukin-2 (rhIL-2) were investigated in patients with MDR-TB.Fifty culture-confirmed patients with MDR-TB were included.Adjunctive immunotherapy with a long period of rhIL-2 is a promising treatment modality for MDR-TB.

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Medicine, the Second Hospital Affiliated to Nanjing Medical University, Nanjing, China.

ABSTRACT

Introduction: Multidrug-resistant tuberculosis (MDR-TB) is a hard-to-treat disease with a poor outcome of chemotherapy. In the present study, the efficacy and safety of recombinant human interleukin-2 (rhIL-2) were investigated in patients with MDR-TB.

Material and methods: Fifty culture-confirmed patients with MDR-TB were included. Twenty-five patients were randomly assigned to the trial group (injection of 500 000 IU of rhIL-2 once every other day at the first, third, fifth and seventh months in addition to standard multidrug therapy) and another 25 patients to the control group with standard multidrug therapy. All patients were monitored clinically, and T-cell subsets were analyzed by flow cytometry.

Results: The rates of sputum negative conversion and X-ray resolution in the trial group were higher than those of the control, and the improvements were significant by completion of treatment. In addition, CD4(+)CD25(+) T cells in the controls rose gradually during treatment. The levels at the end of the seventh month were significantly higher than before, which were also significantly different when compared with those from the trial group at the same time. However, there were no such changes associated with treatment in the trial group. No significant differences appeared in other T cell subsets.

Conclusions: Exogenous IL-2 in the present regimen improves immunity status. Adjunctive immunotherapy with a long period of rhIL-2 is a promising treatment modality for MDR-TB.

No MeSH data available.


Related in: MedlinePlus

Quantities of CD4+CD25+ T cells in different groups before and after treatment*P < 0.05, Significances determined by t test. MDR-TB – multidrug-resistant tuberculosis, IL-2 – interleukin-2.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4495154&req=5

Figure 0002: Quantities of CD4+CD25+ T cells in different groups before and after treatment*P < 0.05, Significances determined by t test. MDR-TB – multidrug-resistant tuberculosis, IL-2 – interleukin-2.

Mentions: We next assessed whether both groups were different in frequencies of CD4+CD25+ T cells. The levels of CD4+CD25+ T cells from the control were found to be elevated after treatment, and were significantly higher at the 7th month as compared with the levels of pretreatment and after one month of anti-TB treatment (p = 0.017). When compared with patients from the rhIL-2 group, the levels of CD4+CD25+ T cells from the control were also significantly higher (p = 0.017). In contrast, the administered rhIL-2 regimen did not induce obvious changes in the number of CD4+CD25+ T cells (Figure 2).


The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis.

Shen H, Min R, Tan Q, Xie W, Wang H, Pan H, Zhang L, Xu H, Zhang X, Dai J - Arch Med Sci (2015)

Quantities of CD4+CD25+ T cells in different groups before and after treatment*P < 0.05, Significances determined by t test. MDR-TB – multidrug-resistant tuberculosis, IL-2 – interleukin-2.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4495154&req=5

Figure 0002: Quantities of CD4+CD25+ T cells in different groups before and after treatment*P < 0.05, Significances determined by t test. MDR-TB – multidrug-resistant tuberculosis, IL-2 – interleukin-2.
Mentions: We next assessed whether both groups were different in frequencies of CD4+CD25+ T cells. The levels of CD4+CD25+ T cells from the control were found to be elevated after treatment, and were significantly higher at the 7th month as compared with the levels of pretreatment and after one month of anti-TB treatment (p = 0.017). When compared with patients from the rhIL-2 group, the levels of CD4+CD25+ T cells from the control were also significantly higher (p = 0.017). In contrast, the administered rhIL-2 regimen did not induce obvious changes in the number of CD4+CD25+ T cells (Figure 2).

Bottom Line: In the present study, the efficacy and safety of recombinant human interleukin-2 (rhIL-2) were investigated in patients with MDR-TB.Fifty culture-confirmed patients with MDR-TB were included.Adjunctive immunotherapy with a long period of rhIL-2 is a promising treatment modality for MDR-TB.

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory Medicine, the Second Hospital Affiliated to Nanjing Medical University, Nanjing, China.

ABSTRACT

Introduction: Multidrug-resistant tuberculosis (MDR-TB) is a hard-to-treat disease with a poor outcome of chemotherapy. In the present study, the efficacy and safety of recombinant human interleukin-2 (rhIL-2) were investigated in patients with MDR-TB.

Material and methods: Fifty culture-confirmed patients with MDR-TB were included. Twenty-five patients were randomly assigned to the trial group (injection of 500 000 IU of rhIL-2 once every other day at the first, third, fifth and seventh months in addition to standard multidrug therapy) and another 25 patients to the control group with standard multidrug therapy. All patients were monitored clinically, and T-cell subsets were analyzed by flow cytometry.

Results: The rates of sputum negative conversion and X-ray resolution in the trial group were higher than those of the control, and the improvements were significant by completion of treatment. In addition, CD4(+)CD25(+) T cells in the controls rose gradually during treatment. The levels at the end of the seventh month were significantly higher than before, which were also significantly different when compared with those from the trial group at the same time. However, there were no such changes associated with treatment in the trial group. No significant differences appeared in other T cell subsets.

Conclusions: Exogenous IL-2 in the present regimen improves immunity status. Adjunctive immunotherapy with a long period of rhIL-2 is a promising treatment modality for MDR-TB.

No MeSH data available.


Related in: MedlinePlus